Loading clinical trials...

Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients | Clinical Trials | Clareo Health

UNKNOWNNA

Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients

NCT04414735•Fundacion Clinic per a la Recerca Biomédica

View on ClinicalTrials.gov

Summary

The aim of the present study is to evaluate the superiority of photopheresis in combination with the standard immunosuppression vs standard immunosuppression alone for the prevention of acute rejection in highly sensitized kidney transplant recipients (cPRA ≥90%). Unicentric, randomized, open study.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Sensitized (cPRA ≥90%) candidates for a deceased-donor kidney transplantation
•Recipients between 18 and 75 years old
•Patients are able to understand and sign informed consent (Annex 1).

Exclusion Criteria

•Participation in another interventional clinical trial.
•Use of Rituximab or Eculizumab at the time of transplant or in the first 24 hours post-transplant.
•Persons with any dependency on the researcher or employee by the responsible institution or researcher. As well as people detained by legal order.

Locations (1)

Deparment of Nephology and Kidney Transplant

Barcelona, Please Select, Spain

Key Dates

Start Date

August 17, 2022

Primary Completion Date

March 1, 2025

Completion Date

December 1, 2025

Last Updated

July 6, 2023

Enrollment

ESTIMATED participants

Conditions

Kidney Transplant Rejection

Interventions

Extracorporeal Photopheresis

OTHER

Contacts

Diekmann

CONTACT

+34932275400 fdiekman@clinic.cat

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

NCT07006532

Kidney Transplant Rejection

View study

RECRUITING

Impact of the Microbiota on the Likelihood of Renal Graft Rejection

NCT04736381

Kidney Transplant Rejection

View study

RECRUITINGNA

Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients

NCT04702022

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 6, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients

Inclusion Criteria

Exclusion Criteria

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

Impact of the Microbiota on the Likelihood of Renal Graft Rejection

Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients

PRObiotics for KIdney Transplantation

Microbiome and Immunosuppression: The Mission Study

Observational Cohort Study Renal Transplantation University Hospitals Leuven